Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06712459 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 2025 to Oct 13, 2025
    • Study sites revised (7)
    v4
  2. Start date: Apr 2025 to Jul 2025
    • Site contacts updated at 7 of 7 sites
    v3
  3. Primary endpoints: 1 to 3
    • Site contacts updated at 7 of 7 sites
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Histological transformation in Splenic Marginal Zone Lymphoma (t-SMZL) represents an unmet clinical and biological need, invariably associated with poor prognosis and reduced overall survival. At the present time, there are no recommended treatments intended specifically to t-SMZL and little is known about t-SMZL genetic complexity. The aim of this study is to provide information that will help clinicians to better understand the complexity of the disease. The information gained from this study will also lead to more specific and effective treatment for patients with t-SMZL.
Trial Details
NCT Number NCT06712459
Lead Sponsor International Extranodal Lymphoma Study Group (IELSG)
Conditions
(from sponsor)		 Transformed Splenic Marginal Zone Lymphoma
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov